Выпуск
Pharmaceutical Executive Daily: Merck Acquires SPR2015 in $2.13 Billion Licensing Deal
Pharmaceutical Executive · 28 сентября 2026 г. · 3 мин
Merck licenses a preclinical KRAS G12D inhibitor from SciBrunch, FDA approves Olumiant, Juvmo, and Atebrioz across three separate indications, and Matthew Montes de Oca makes the case for compounding pharmacies to set their own safety standards.